Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret,
Nicolas Boissel,
Nathalie Helevaut,
Jordan Madic,
Olivier Nibourel,
Alice Marceau-Renaut,
Maxime Bucci,
Sandrine Geffroy,
Karine Celli-Lebras,
Sylvie Castaigne,
Xavier Thomas,
Christine Terré,
Hervé Dombret,
Claude Preudhomme,
Aline Renneville
Affiliations
Yann Ferret
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France;INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France;University of Lille, F-59000, Paris, France
Nicolas Boissel
Hematology Department, Saint-Louis Hospital, AP-HP, Paris, France;EA3518, Institut Universitaire d’Hématologie (IUH), University 7 Paris Diderot, Paris, France
Nathalie Helevaut
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
Jordan Madic
Circulating Biomarkers Laboratory, Curie Institute, Paris, France
Olivier Nibourel
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France;INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France;University of Lille, F-59000, Paris, France
Alice Marceau-Renaut
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France;INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France;University of Lille, F-59000, Paris, France
Maxime Bucci
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
Sandrine Geffroy
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
Karine Celli-Lebras
Acute Leukemia French Association (ALFA) coordination, Saint-Louis Hospital, AP-HP, Paris, France
Sylvie Castaigne
Hematology Department, Versailles Hospital, Le Chesnay, France
Xavier Thomas
Hematology Department, Lyon Sud Hospital, Pierre Benite, France
Christine Terré
Cytogenetic Laboratory, Versailles Hospital, Le Chesnay, France
Hervé Dombret
Hematology Department, Saint-Louis Hospital, AP-HP, Paris, France;EA3518, Institut Universitaire d’Hématologie (IUH), University 7 Paris Diderot, Paris, France
Claude Preudhomme
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France;INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France;University of Lille, F-59000, Paris, France
Aline Renneville
Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France;INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France;University of Lille, F-59000, Paris, France
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia, since these mutations collectively occur in 15–20% of cases of acute myeloid leukemia and now represent druggable targets. We employed droplet digital polymerase chain reaction assays to quantify IDH1R132, IDH2R140, and IDH2R172 mutations on genomic DNA in 322 samples from 103 adult patients with primary IDH1/2 mutant acute myeloid leukemia and enrolled on Acute Leukemia French Association (ALFA) - 0701 or -0702 clinical trials. The median IDH1/2 mutant allele fraction in bone marrow samples was 42.3% (range, 8.2 – 49.9%) at diagnosis of acute myeloid leukemia, and below the detection limit of 0.2% (range,
